Based on these results, a clinical trial is testing abemaciclib, a CDK4/6 inhibitor, as a single agent in ED-SCLC patients with wild-type RB1, with platinum refractory disease (ClinicalTrials.gov Identifier NCT04010357). Here, CDK4 is linked to small cell lung carcinoma.